Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease–like pathology and cognitive decline - vom Berg, Johannes; Prokop, Stefan; Miller, Kelly R; Obst, Juliane; Kälin, Roland E; Lopategui-Cabezas, Ileana; Wegner, Anja; Mair, Florian; Schipke, Carola G; Peters, Oliver; Winter, York; Becher, Burkhard; et al. (Nature medicine, 2012)
Keywords: 631/250/127/1213; 631/250/516; 692/699/375/365/1283; 692/700/139/422; Alzheimer Disease - pathology; Alzheimer's disease; Amyloid beta-Peptides - metabolism; Analysis of Variance; Animals; Antibodies - administration & dosage; Antibodies - pharmacology; Biomedicine; Blotting, Western; Cancer Research; Care and treatment; Cognition & reasoning; Cognition - drug effects; Cognitive ability; Complications and side effects; Disease; DNA Primers - genetics; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Genetic aspects; Health aspects; Infectious Diseases; Injections, Intraperitoneal; Interleukin-12 - genetics; Interleukin-12 - immunology; Interleukin-12 - metabolism; Interleukin-12 Subunit p40 - cerebrospinal fluid; Interleukin-12 Subunit p40 - genetics; Interleukin-12 Subunit p40 - immunology; Interleukin-12 Subunit p40 - metabolism; Interleukins; Memory, Disorders of; Metabolic Diseases; Mice; Mice, Transgenic; Microglia - metabolism; Molecular Medicine; Neurosciences; Pathology; Real-Time Polymerase Chain Reaction; Risk factors; Signal Transduction - drug effects; Signaling; Statistics; Cuba; Switzerland; Germany